Anaplastic lymphoma kinase (ALK) has been implicated as a key driver in several malignancies, including non-small cell lung cancer and anaplastic large cell lymphoma, through various activating mutations, fusions, and amplifications [27,28]. This evidence concerns the gene ALK and anaplastic large cell lymphoma.